Low Creatinine-to-Cystatin C Ratio Tied to Lower Muscle Volume in Midlife Women
By Elana Gotkine HealthDay Reporter
MONDAY, March 31, 2025 -- Among middle-aged women, low creatinine-to-cystatin C ratio (CCR) at baseline is associated with lower fat-free muscle volumes and poorer gait speeds 6.6 years later, according to a study published online March 18 in Menopause.
Darren Yuen Zhang Tan, from the National University of Singapore, and colleagues examined the longitudinal relationship of baseline CCR with muscle volumes measured by magnetic resonance imaging (MRI) and objectively measured muscle strength and physical performance after a follow-up of 6.6 years. Participants included 891 women (baseline mean age, 56.2 ± 6.0 years) who attended baseline and follow-up visits and underwent objectively measured muscle strength and physical performance assessments and MRI.
The researchers observed an association between baseline low CCR and lower MRI-measured muscle volumes and poorer physical function 6.6 years later. After adjustment for covariates, mean fat-free thigh muscle of the low-CCR group was 0.350 L lower than in the high-CCR group. In addition, there were associations seen for the low-CCR group with 0.029 m/s slower mean usual gait and 0.049 m/s slower mean narrow gait speeds. No association was seen for CCR with handgrip strength and repeated chair stands and one-leg stand tests.
"Because both muscle volume and poorer gait speed are constituents of current diagnostic criteria of sarcopenia, CCR may be a tool to help identify midlife women at risk of developing early sarcopenia and associated probability of adverse health outcomes," Stephanie Faubion, M.D., medical director of The Menopause Society, said in a statement. "Regardless of baseline risk, all midlife women should strive to mitigate loss of muscle mass with regular resistance training and adequate dietary protein intake to help prevent frailty as they age."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-04-01 06:00
Read more

- scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the Furoscix Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease
- Swallowing Disorder Not Widely Known, Understood By Public
- Alnylam Announces FDA Approval of Amvuttra (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)
- FDA Increases Testing For Heavy Metals In Baby Formula
- Could Your Cup of Tea Help Remove Lead From Drinking Water?
- Treating Male Partners Reduces Recurrence in Bacterial Vaginosis
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions